18 patents
Utility
Genetically Modified Primary Cells for Allogeneic Cell Therapy
11 Jan 24
Provided are engineered cells, such as engineered primary cells, containing one or more modifications, such as genetic modifications, for use in allogeneic cell therapy.
Sonja SCHREPFER, Xiaomeng HU
Filed: 14 Aug 23
Utility
Methods and Compositions for Modulating Car-t Activity
4 Jan 24
Disclosed herein are engineered cells and/or hypoimmunogenic cells including engineered and/or hypoimmunogenic stem cells, engineered and/or hypoimmunogenic cells differentiated therefrom, engineered and/or hypoimmunogenic CAR-T cells (primary or differentiated from engineered and/or hypoimmunogenic stem cells) and related methods of their use and generation.
Sonja Schrepfer, Lindong Weng, Terry J. Fry
Filed: 21 Jun 23
Utility
Hepatocyte-like Cells
30 Nov 23
Provided herein are hepatocyte-like cells with enhanced in vitro ureagenesis capability and methods for producing and using such cells.
John Michael Rukstalis, Ryan M. Hasselkus, Elizabeth Suzanne Howe Vera
Filed: 13 Oct 21
Utility
Modified Anti-viral Binding Agents
28 Sep 23
Provided herein are methods of treating a virus infection, such as a coronavirus infection, by delivering to a subject in need a binding agent, wherein the binding agent comprising (i) at least one binding domain that binds to a viral protein expressed on the surface of a virus, and (ii) a modified Fc domain that exhibits either (a) reduced binding to an Fc activating receptor or (b) increased binding to an Fc inhibitory receptor compared to a wild-type Fc domain.
Richard C. MULLIGAN, Michael J. VOLLES
Filed: 30 Aug 21
Utility
Hypoimmunogenic Neural Cells for the Treatment of Neurological Disorders and Conditions
21 Sep 23
Disclosed herein are cells including neural cells that evade immune recognition such as microglial response and related methods of their use and generation.
Sonja SCHREPFER, Rebeca RAMOS-ZAYAS
Filed: 25 Mar 21
Utility
Methods of Treating Sensitized Patients with Hypoimmunogenic Cells, and Associated Methods and Compositions
21 Sep 23
Disclosed herein are hypoimmunogenic cells for administering to a sensitized patient.
Sonja Schrepfer, Steve Harr, Charles E. Murry
Filed: 12 Aug 21
Utility
Modification of Blood Type Antigens
31 Aug 23
Provided herein are cells with a gene modification of an ABO gene, RHD gene, and/or FUT1 gene.
William DOWDLE, Andrew MAY, Sonja SCHREPFER
Filed: 12 Jan 21
Utility
CD8-SPECIFIC Antibody Constructs and Compositions Thereof
17 Aug 23
Disclosed herein are antibodies or antigen binding fragments thereof that specifically bind human CD8.
Patricia Ann CRUITE, Shirisha AMATYA, Hugh HARDING, Lauren Pepper MacKenzie
Filed: 17 Nov 22
Utility
Safety Switches for Regulation of Gene Expression
2 Mar 23
Disclosed herein are cells including pluripotent stem cells that conditionally express an immunosuppressive factor and related methods of their use and generation.
Ryan CLARKE, Greg HOFFMAN, Andrew MAY, Eleonore THAM
Filed: 15 Jan 21
Utility
CD24 Expressing Cells and Uses Thereof
26 Jan 23
Disclosed herein are cells including cells expressing CD24 and related methods of their use and generation.
Sonja SCHREPFER, Steve HARR
Filed: 24 Aug 20
Utility
Methods and Compositions for Modulating Car-t Activity
20 Oct 22
Disclosed herein are engineered cells and/or hypoimmunogenic cells including engineered and/or hypoimmunogenic stem cells, engineered and/or hypoimmunogenic cells differentiated therefrom, engineered and/or hypoimmunogenic CAR-T cells (primary or differentiated from engineered and/or hypoimmunogenic stem cells) and related methods of their use and generation.
Sonja Schrepfer, Lindong Weng, Terry J. Fry
Filed: 23 Dec 21
Utility
CD8-SPECIFIC Antibody Constructs and Compositions Thereof
20 Oct 22
Disclosed herein are antibodies or antigen binding fragments thereof that specifically bind human CD8.
Patricia A. CRUITE, Shirisha AMATYA, Hugh HARDING, Lauren Pepper MACKENZIE
Filed: 7 Apr 22
Utility
Immunosuppressive Therapies for Use with Cardiomyocyte Cell Therapies, and Associated Methods and Compositions
22 Sep 22
Provided are methods and uses related to cardiomyocyte cell therapies involving the administration of immunosuppressive agents for reducing or preventing rejection of administered allogeneic cardiomyocytes.
Robert Scott THIES, Charles E. MURRY
Filed: 2 Mar 22
Utility
DUX4 Expressing Cells and Uses Thereof
25 Aug 22
Disclosed herein are cells expressing DUX4 including stem cells, differentiated cells thereof, primary T cells, and chimeric antigen receptor T cells, as well as related methods of their use and generation.
Chad A. Cowan, Ryan S. McQuade, Sonja Schrepfer
Filed: 31 Jul 20
Utility
Use of CD8-TARGETED Viral Vectors
4 Aug 22
Provided herein are methods of transducing resting or non-activated T cells using CD8-targeted viral vectors.
Christopher BANDORO, Patricia CRUITE, Kutlu ELPEK, Akinola Olumide EMMANUEL, Lauren Pepper MACKENZIE, Jagesh Vijaykumar SHAH, Kyle Marvin TRUDEAU
Filed: 10 Jan 22
Utility
Methods and Compositions for Modulating Car-t Activity
21 Jul 22
Disclosed herein are engineered cells and/or hypoimmunogenic cells including engineered and/or hypoimmunogenic stem cells, engineered and/or hypoimmunogenic cells differentiated therefrom, engineered and/or hypoimmunogenic CAR-T cells (primary or differentiated from engineered and/or hypoimmunogenic stem cells) and related methods of their use and generation.
Sonja Schrepfer, Lindong Weng, Terry J. Fry
Filed: 7 Feb 22
Utility
Methods of Treating Sensitized Patients with Hypoimmunogenic Cells, and Associated Methods and Compositions
17 Feb 22
Disclosed herein are hypoimmunogenic cells for administering to a sensitized patient.
Sonja Schrepfer, Steve Harr, Charles E. Murry
Filed: 12 Aug 21
Utility
Targeted Lipid Particles and Compositions and Uses Thereof
18 Nov 21
Provided herein are lipid particles containing a lipid bilayer enclosing a lumen or cavity, a henipavirus F protein molecule or biologically active portion thereof, and a targeted envelope protein containing a henipavirus envelope attachment glycoprotein G (G protein) or biologically active portion thereof and a binding domain, such as a single domain antibody (sdAb) variable domain.
Kyle Marvin TRUDEAU, Christopher BANDORO, Lauren Pepper MACKENZIE, Jagesh Vijaykumar SHAH, Geoffrey A. VON MALTZAHN, Jacob Rosenblum RUBENS, Michael Travis MEE
Filed: 30 Mar 21
- Prev
- 1
- Next
Patents are sorted by USPTO publication date, most recent first